SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending due to significant institutional interest surrounding its pivot toward AI-focused power infrastructure and the anticipation of upcoming hyperscaler lease announcements. The community is actively discussing the stock's potential for a valuation re-rating, with traders highlighting recent technical momentum and the firm's strategic positioning ahead of index fund inflows.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following strong 52-week VELA trial results that demonstrate clinical superiority and durability, fueling community speculation about a potential buyout. Investors are actively discussing the company's best-in-class profile and upcoming regulatory milestones, with many viewing the asset as a prime candidate for acquisition by a major pharmaceutical firm.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following positive topline Phase 3 Emerge study results, which showed statistically significant and clinically meaningful improvement in major depressive disorder. Community discussion remains highly focused on the upcoming readouts for the company's GAD programs, with investors debating the stock's potential for a broader re-rate while weighing the ongoing risks of cash burn and future dilution.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is trending as investors rally around a significant $2 billion convertible senior notes offering, with the community highly focused on the company's strategic use of proceeds for share repurchases and aggressive global expansion. Traders are closely monitoring the stock's reclaim of key technical moving averages, fueling intense debate between long-term bulls betting on ecosystem growth and day traders navigating sharp intraday volatility.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as a primary beneficiary of the AI-driven memory supercycle, with the community actively debating whether its parabolic rise represents sustainable structural growth or a speculative bubble reminiscent of the dot-com era. Traders remain sharply divided between aggressive bulls targeting further highs and skeptics calling for a correction, while attention shifts toward upcoming earnings catalysts in the broader semiconductor sector.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to advance solid-state battery development and manufacturing processes. The community is actively discussing whether this partnership marks a major milestone for the companys commercial viability, with many investors debating the long-term potential for expansion into broader sectors like robotics and AI data centers.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is seeing significant volatility after the FDA placed a clinical hold on its RGX-111 Hurler syndrome program and the related RGX-121 study due to a reported brain tumor, raising concerns about the safety of its common AAV9 gene therapy platform ahead of an upcoming PDUFA date. While analysts at Leerink have characterized the subsequent sell-off as an overreaction based on the program's limited financial contribution to the broader pipeline, community discourse remains split between those viewing the pullback as a buying opportunity and others bracing for a potential Complete Response Letter regarding the pending RGX-121 application.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is experiencing significant volatility and social media attention following an announcement regarding a co-development deal with Midjourney, which investors are analyzing as a potential long-term catalyst for the company's semiconductor-based ultrasound technology. While bulls highlight institutional backing and the transformative potential of AI in medical imaging, bears are actively debating the high valuation, persistent cash burn, and the risk of a share offering following the rapid price move.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending following reports that it is nearing a multi-billion dollar cash deal to acquire Apogee Therapeutics, a move aimed at bolstering its immunology portfolio with longer-acting alternatives to current blockbuster therapies. Investors and industry followers are closely watching this development as a significant M&A move that highlights the ongoing consolidation and strategic focus within the biotech and inflammatory disease sectors.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors weigh strong DefenCath utilization and raised revenue guidance against ongoing concerns regarding the impending TDAPA reimbursement cliff and the company's long-term growth strategy. While bulls highlight institutional support and successful patent litigation, the community remains divided over management's execution and the timeline for realizing potential from the Melinta portfolio and pipeline assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Industry Outlook Highlights Logitech, Turtle Beach, Immersion and TransAct

Logitech, Turtle Beach, Immersion and TransAct stand out as industry headwinds persist, supported by gaming, wireless, haptic and RFID demand.

4 Computer Peripheral Stocks to Watch Despite Industry Headwinds

Despite a challenging macroeconomic environment, few companies in the Zacks Computer-Peripheral Equipment industry, including LOGI, TBCH, IMMR and TACT, are worth watching due to their end-market strength.

Immersion (NASDAQ:IMMR) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

Immersion (NASDAQ:IMMR) Stock Price Passes Above Two Hundred Day Moving Average - Here's What Happened...

Ex-Div Reminder for Immersion (IMMR)

Looking at the universe of stocks we cover at Dividend Channel, on 4/20/26, Immersion Corp (Symbol: IMMR) will trade ex-dividend, for its quarterly dividend of $0.075, payable on 5/1/26. As a percentage of IMMR's recent stock price of $6.09, this dividend works out to approxima...

Immersion (NASDAQ:IMMR) Issues Quarterly Earnings Results

Immersion (NASDAQ:IMMR - Get Free Report) issued its quarterly earnings results on Monday. The software maker reported $0.36 earnings per share (EPS) for the quarter. Immersion had a return on equity...

Immersion Corporation Declares Quarterly Dividend of $0.08 (NASDAQ:IMMR)

Immersion Corporation (NASDAQ:IMMR) declared a quarterly dividend on Wednesday, April 1st. Investors of record on Monday, April 20th will be paid a dividend of 0.075 per share by the software maker...

Immersion Corporation Receives Nasdaq Staff Additional Delinquency Notice

Immersion Corporation (Immersion, the Company, we, us or our) (Nasdaq: IMMR), a leading provider of technologies for haptics, today announced that, on March 24, 2026, the Company received an...

Immersion (NASDAQ:IMMR) Announces Earnings Results, Misses Expectations By $0.18 EPS

Immersion (NASDAQ:IMMR - Get Free Report) announced its earnings results on Wednesday. The software maker reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus...

Immersion (IMMR) Expected to Announce Quarterly Earnings on Wednesday

Immersion (NASDAQ:IMMR) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 11. (View Earnings Report at...

Immersion Corporation Receives Nasdaq Staff Determination Letter; Will Seek Hearing & Continued Listing

Immersion Corporation (Immersion, the Company, we, us or our) (Nasdaq: IMMR), a leading provider of technologies for haptics, today announced that, on February 10, 2026, the Company received a Staff...

Immersion Corp. engages in the creation, design, development and licensing of patented haptic innovations and software. The firm offers touch sense platform and design services. It focuses on the following target application areas: mobile devices, wearable, consumer, mobile entertainment and other content, console gaming, automotive, medical, and commercial. The company was founded in 1993 and is headquartered in Aventura, FL.

Immersion Corp

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.68
Prev Close	$6.46
Open	$6.58
Dividend Yield	1.24%
50-Day Moving Average	$6.32
Beta	1.16
Avg. Volume	541,298.51
PE Ratio	-33.43

52-Week High	$8.15
52-Week Low	$5.25
Market Capitalization	$221.11M
EPS (Annual)	$1.90
Price to Book	0.75
Revenue Per Employee	N/A

IMMRImmersion Corp

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMMR News